Abstract
Rheumatoid arthritis (RA) is a chronic disease characterized by an immune mediated inflammatory synovitis that leads to joint destruction, functional impairment, and reduced quality of life. Thus, treatment goals should be longterm substantial relief of pain, arrested joint inflammation and damage, and improved function. Conventional (nonbiologic) DMARDs use is the first step of this debilitating disease treatment but in many patients, this is inadequate and other forms of therapy are required. Advances in the current knowledge of pathogenetic mechanisms of rheumatoid arthritis have contributed to the development of biological therapy, and translated research findings into clinical practice. TNF-alpha (infliximab, etanercept, adalimumab), IL-1 (anakinra) and IL-6 (tocilizumab) inhibitors, a B-cell depleting agent (rituximab) and a drug blocking T-cell costimulation (abatacept) have been approved for rheumatoid arthritis. In this text, the biologic therapies which are currently used in the patients with RA will be reviewed in the company of latest evidences.
Keywords: Rheumatoid arthritis, biologic therapy, anti-TNF therapy, golimumab, certolizumab, abatacept, rituximab, tocilizumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Biologic Agents for Treatment of Rheumatoid Arthritis
Volume: 9 Issue: 1
Author(s): Bulent Butun
Affiliation:
Keywords: Rheumatoid arthritis, biologic therapy, anti-TNF therapy, golimumab, certolizumab, abatacept, rituximab, tocilizumab
Abstract: Rheumatoid arthritis (RA) is a chronic disease characterized by an immune mediated inflammatory synovitis that leads to joint destruction, functional impairment, and reduced quality of life. Thus, treatment goals should be longterm substantial relief of pain, arrested joint inflammation and damage, and improved function. Conventional (nonbiologic) DMARDs use is the first step of this debilitating disease treatment but in many patients, this is inadequate and other forms of therapy are required. Advances in the current knowledge of pathogenetic mechanisms of rheumatoid arthritis have contributed to the development of biological therapy, and translated research findings into clinical practice. TNF-alpha (infliximab, etanercept, adalimumab), IL-1 (anakinra) and IL-6 (tocilizumab) inhibitors, a B-cell depleting agent (rituximab) and a drug blocking T-cell costimulation (abatacept) have been approved for rheumatoid arthritis. In this text, the biologic therapies which are currently used in the patients with RA will be reviewed in the company of latest evidences.
Export Options
About this article
Cite this article as:
Butun Bulent, Biologic Agents for Treatment of Rheumatoid Arthritis, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9 (1) . https://dx.doi.org/10.2174/187152310790711692
DOI https://dx.doi.org/10.2174/187152310790711692 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Naturally Occurring NF-κB Inhibitors
Mini-Reviews in Medicinal Chemistry Affinity-Based Methods in Drug-Target Discovery
Current Drug Targets Benzo[a]pyrene Toxicity and Inflammatory Disease
Current Rheumatology Reviews In Vitro Metabolism of Leflunomide by Mouse and Human Liver Microsomes
Drug Metabolism Letters Opto-Acoustic Imaging of Drug Discovery Biomarkers
Current Pharmaceutical Biotechnology The Role of TNF and Its Family Members in Inflammation and Cancer: Lessons from Gene Deletion
Current Drug Targets - Inflammation & Allergy Aluminum Excytotoxicity and NeuroAutotoImmunity: The Role of the Brain Expression of CD32+ (FcγRIIa), ICAM-1+ and CD3ع in Aging
Current Aging Science Cardiovascular Disease in Systemic Lupus Erythematosus: The Role of Traditional and Lupus Related Risk Factors
Current Cardiology Reviews Assessment of the Physicochemical Properties and Stability for Pharmacokinetic Prediction of Pyrazinoic Acid Derivatives
Current Drug Metabolism Comprehensive Analysis of the mRNA-lncRNA Co-expression Profile and ceRNA Networks Patterns in Chronic Hepatitis B
Current Genomics Radiolabelled Probes Targeting Infection and Inflammation for Personalized Medicine
Current Pharmaceutical Design Human Complex Trait Genetics: Lifting the Lid of the Genomics Toolbox - from Pathways to Prediction
Current Genomics Retinoids as Differentiating Agents in Oncology: A Network of Interactions with Intracellular Pathways as the Basis for Rational Therapeutic Combinations
Current Pharmaceutical Design Endothelial Progenitor Cells as Mediators of the Crosstalk between Vascular Repair and Immunity: Lessons from Systemic Autoimmune Diseases
Current Medicinal Chemistry Chemical Inhibition of Matrix Metalloproteinases for Periodontal Treatment
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Hepatic Manifestations in Juvenile Systemic Lupus Erythematosus
Recent Patents on Inflammation & Allergy Drug Discovery Adenosine and Stroke: Maximizing the Therapeutic Potential of Adenosine as a Prophylactic and Acute Neuroprotectant
Current Neuropharmacology Natural Products Triggering Biological Targets- A Review of the Anti-Inflammatory Phytochemicals Targeting the Arachidonic Acid Pathway in Allergy Asthma and Rheumatoid Arthritis
Current Drug Targets Autoimmune (Auto-inflammatory) Syndrome Induced by Adjuvants (ASIA) – Animal Models as a Proof of Concept
Current Medicinal Chemistry A New Drug Candidate (GEMSP) for Multiple Sclerosis
Current Medicinal Chemistry